Journal article icon

Journal article

[Adjuvant tamoxifen duration: more large-scale randomized evidence is needed]

Abstract:

The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) overview of worldwide evidence has demonstrated that a few years of adjuvant tamoxifen produces a moderate but definite benefit in long-term survival. However, there is major uncertainty regarding the optimal duration of tamoxifen treatment and in particular, as to whether, after a few years on tamoxifen, most women should stop or should continue for several years longer. ATLAS (Adjuvant Tamoxifen: Longer Against Shorter) is a la...

Expand abstract

Actions


Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Nuffield Department of Population Health
Sub department:
Clinical Trial Service Unit
Role:
Author
Journal:
Gan to kagaku ryoho. Cancer and chemotherapy
Volume:
24
Issue:
10
Pages:
1203-1209
Publication date:
1997-08-01
ISSN:
0385-0684
Source identifiers:
75345
Language:
Japanese
Keywords:
Pubs id:
pubs:75345
UUID:
uuid:f9460046-3e5b-4e05-9aa4-22cf76393f0f
Local pid:
pubs:75345
Deposit date:
2012-12-19

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP